Literature DB >> 23455843

Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia.

Meltem Ercan1, Sinem Firtina1, Dildar Konukoglu1.   

Abstract

OBJECTIVE: In this study, we aimed to investigate the alterations in plasma viscosity and whether there was a relationship between plasma viscosity and endothelial dysfunction markers such as nitric oxide (NOx), asymmetric dimethylarginine (ADMA) and oxidized Low Density Lipoprotein (oxLDL) in dyslipidemic subjects. MATERIAL AND
METHOD: 35 subjects with normolipidemia and 30 subjects with hyperlipidemia were involved in this study. Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL. Plasma total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, total protein, albumin levels and NOx were determined by enzymatic methods using commercial kits. Plasma ADMA concentrations and serum levels of total oxLDL were determined by ELISA. Plasma viscosity was measured by Harkness capillary viscometer. RESULT: Plasma viscosity, ADMA and oxLDL values were significantly higher in subjects with dyslipidemia than in subjects with normolipidemia. Plasma NOx concentration was decreased in dyslipidemic subjects compared to the normo-lipidemic subjects. We found that fibrinogen had no effect upon plasma viscosity in selected patients with dyslipidemia.
CONCLUSION: Our results demonstrated that the rheological impairment of dyslipidemic patients was related with endothelial dysfunction and this was a possible cause of both micro and macrovascular complications. Therefore, as plasma viscosity is also a sensitive parameter, it can add useful information about the diagnosis and treatment of various disorders, and it should be utilized more frequently in clinical medicine.

Entities:  

Keywords:  Atherosclerosis; Oxidized LDL; asymmetric dimethylarginine; nitric oxide; plasma viscosity; shear stress

Mesh:

Substances:

Year:  2014        PMID: 23455843     DOI: 10.3233/CH-131706

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  2 in total

1.  Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats.

Authors:  Dongdan Zheng; Qing Liang; FanFang Zeng; Zhuocheng Mai; Anping Cai; Ruofeng Qiu; Rulin Xu; Dongjuan Li; Weiyi Mai
Journal:  Lipids Health Dis       Date:  2015-05-02       Impact factor: 3.876

2.  Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.

Authors:  Andrzej Surdacki; Olga Kruszelnicka; Tomasz Rakowski; Aleksandra Jaźwińska-Kozuba; Jacek S Dubiel
Journal:  Cardiovasc Diabetol       Date:  2013       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.